Approach-Avoidance Computational Framework for Predicting Behavioral Therapy Outcome (AAC-BeT)

  • STATUS
    Recruiting
  • End date
    Jun 30, 2025
  • participants needed
    220
  • sponsor
    Laureate Institute for Brain Research, Inc.
Updated on 2 November 2021
depression
anxiety
behavior therapy
behavioral therapy
depressive symptoms
depressed mood
psychotherapy
anxiety disorder

Summary

Depression and anxiety disorders rank in the top ten causes of years lived with disability. Less than 50% of patients experiencing long-lasting improvements to current gold-standard treatments. Two gold-standard behavioral interventions include behavioral activation, focused on enhancing approach behavior towards meaningful activities, and exposure-based therapy, focused on decreasing avoidance and challenging negative expectations. While these interventions have divergent treatment targets, there is little knowledge to inform which strategies should be used in the frequent case of comorbid anxiety and depression. Approach-avoidance decision-making paradigms focus on assessing responses when faced with potential rewards and threats, tapping into processes important for both anxiety and depression as well as behavioral activation and exposure-based therapy.

For this study, investigators will recruit individuals reporting both anxiety and depression symptoms and randomize them to one of three different interventions: (1) behavioral activation, (2) exposure-based therapy, and a non-specific therapy approach (3) supportive therapy. Participants will complete clinical, self-report, behavioral, and functional magnetic resonance imaging (fMRI) assessments before and after therapy. Investigators will use a computational approach to model factors that may influence one's behavior during approach-avoidance decision-making, including drives to avoid threat versus approach reward and confidence versus uncertainty in one's decisions.

This project will accomplish the following aims (1) Determine how changes in brain and behavior responses during approach-avoidance conflict relate to changes in mental health symptoms with the different therapy approaches, (2) Determine the degree to which baseline brain and behavior responses during approach-avoidance conflict predict response to the different therapy approaches, above and beyond the influence of demographics and baseline symptom severity. In addition, by including peripheral blood draws and measures of grace matter volume, the project will also accomplish the following aims: (1) Determine whether kynrenine metabolites measures peripherally may be beneficial as a biomarker of treatment response and (2) determine whether there is an association between change in kynurenine metabolites and changes in gray matter volume with treatment.

Results will enhance understanding of how different psychotherapy approaches (behavioral activation, exposure-based therapy) may impact brain responses and decisions when faces with potential reward versus threat and approach versus avoidance drives. In addition, results will have important implications concerning the potential for a more personalized approach to psychotherapy, enhancing knowledge of which types of therapy strategies may be most beneficial for which individuals.

Details
Condition Anxiety Disorders (Pediatric), Generalized Anxiety Disorder (GAD), Anxiety, Anxiety Symptoms, anxiety disorder, miserable, Anxiety Disorders, Depression, depressed mood, Depression (Adolescent), Depression (Pediatric), Generalized Anxiety Disorder (GAD - Pediatric), Endogenous depression, Depression (Treatment-Resistant), Depression (Major/Severe), Depression (Adult and Geriatric), ANXIETY NEUROSIS, depressive disorders, anxious, Depressed, depressive disorder
Treatment Supportive Therapy, Behavioral Activation, Exposure-based therapy
Clinical Study IdentifierNCT04426461
SponsorLaureate Institute for Brain Research, Inc.
Last Modified on2 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

score >55 on both the PROMIS Anxiety and PROMIS Depression scales
score >5 on any one item of the SDS
able to provide informed consent
report of anxiety and depressive symptoms as areas of clinical concern
sufficient English proficiency to complete procedures

Exclusion Criteria

significant or unstable physical or mental health conditions (e.g., immediate suicidal intent) requiring medical attention
history of bipolar, psychotic, cognitive, obsessive compulsive disorder, posttraumatic stress disorder (PTSD)
history of moderate to severe substance use disorder over the past year
diagnosis of neurologic disorders
MRI contra-indications (e.g., metal in body)
uncorrected vision/hearing problems
current, regular benzodiazepine use
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note